FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines has been appointed by EUSA Pharma to extend its current exclusive distribution of Qarziba® via Managed Access Program in Russia/CIS region, to cover additionally the LATAM(1) and APAC(2) regions.
Qarziba® (Dinutuximab beta) is an anti-GD2 monoclonal antibody that has shown to significantly improve event-free and overall survival in children with high-risk neuroblastoma, with an acceptable safety profile. Dinutuximab beta EUSA has been approved in May 2017 by the EU medicines agency (EMA) for the treatment of patients with high-risk neuroblastoma. Under this program, EUSA Pharma will make Qarziba® (Dinutuximab beta) available in collaboration with FarmaMondo in response to unsolicited requests by oncologists and other clinical specialists on an individual named-patient basis in accordance with local and international regulations.
Program Contact details
All requests must be submitted by the treating physician on behalf of the patient. Healthcare providers can obtain details about the Dinutuximab-beta Access Program by contacting FarmaMondo’s dedicated email address Qarziba@farmamondo.com
FarmaMondo is a Swiss-based pharmaceutical company with a focus on providing paid access to unlicensed medicines. Our global footprint includes commercial operations in more than 70 markets, headquartered from Switzerland with regional hubs in Europe, Asia and Latin America.
For more information about FarmaMondo please visit www.farmamondo.com.
About EUSA Pharma
EUSA Pharma is a specialty pharmaceutical company with commercial operations in the US and Europe, and a wider distribution network in approximately 40 countries around the world.
EUSA Pharma has a focus on oncology and oncology supportive care, having currently a broad portfolio of approved and named-patient specialty hospital products, which the company has ambitious plans to expand through acquisition and in-licensing.
For more information about EUSA Pharma please visit www.eusapharma.com.